New hope for kids with Ultra-Rare leukemia: re-engineered immune cell trial opens
NCT ID NCT04276870
Summary
This study is testing a personalized cell therapy called CART19 for children and young adults with specific, very high-risk types of B-cell acute lymphoblastic leukemia (B-ALL) that are difficult to treat with standard methods. It aims to see if using the patient's own modified immune cells can control the cancer and improve survival. The trial is for patients up to age 29 who have certain rare genetic forms of B-ALL or whose cancer has returned in the central nervous system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC AND YOUNG ADULT PATIENTSWITH HYPODIPLOID OR T(17;19) B-ALL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.